Search clinical trials for: Pituitary Adenylate Cyclase-Activating Polypeptide

Total 23 results

Danish Headache Center

Completed

PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load

Migraine Without Aura

Denmark
Danish Headache Center

Recruiting

Hypersensitivity to PACAP-38 in Post-Traumatic Headache

Post-Traumatic Headache

Denmark
Song Guo

Completed

The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients

Migraine Without Aura

Denmark
Danish Headache Center

Completed

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Pain | Migraine | Headache

Denmark
Glostrup University Hospital, Copenhagen
Bispebjerg Hospital; Lundbeck Foundation; University Hospital, Gentofte, Copenhagen and other collaborators

Completed

Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance

Migraine Without Aura

Denmark
Danish Headache Center

Completed

PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

Migraine Without Aura

Denmark
Amgen

Completed

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

Migraine

United States, Belgium, Netherlands
Danish Headache Center

Completed

The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers

Headache, Migraine

Denmark
Danish Headache Center

Completed

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

Migraine Without Aura

Denmark
Danish Headache Center

Completed

PACAP27 Headache Properties in Migraine Without Aura Patients

Migraine Without Aura

Denmark
Danish Headache Center

Completed

Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Migraine

Denmark
Danish Headache Center

Unknown

PACAP-38 Infusion in Patients With Cluster Headache

Cluster Headache

Denmark
University Diabetes & Endocrine Consultants
Amylin Pharmaceuticals, LLC.

Completed

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

IDDM

United States
AstraZeneca

Completed

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Obesity | Overweight

United States
Stanley Jordan, MD
CSL Behring

Completed

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Kidney Transplantation

United States
Michael Levy
ViroPharma

Completed

C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation

Neuromyelitis Optica

United States
CSL Behring

Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Antibody-mediated Rejection

United States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
CSL Behring
Chiltern International Inc.

Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

Includes: Hereditary Angioedema

United States, Denmark, Germany, Switzerland
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
Radboud University Medical Center
UMC Utrecht; Prothya Biosolutions

Completed

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II (VECTORII)

Sepsis | Inflammation | Endotoxemia | Innate Immune Response

Netherlands
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel

Search clinical trials for: Pituitary Adenylate Cyclase-Activating Polypeptide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations